Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin

Background & Aims: Recently, we reported that liver Label Retaining Cancer Cells (LRCC) can initiate tumors with only 10 cells and are relatively resistant to the targeted drug Sorafenib, a standard of practice in advanced hepatocellular carcinoma (HCC). LRCC are the only cancer stem cells (CSC)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Cancer
Main Authors: Xin, Hong-Wu, Ambe, Chenwi M., Miller, Tyler C., Chen, Jin-Qiu, Wiegand, Gordon W., Anderson, Andrew J., Ray, Satyajit, Mullinax, John E., Hari, Danielle M., Koizumi, Tomotake, Godbout, Jessica D., Goldsmith, Paul K., Stojadinovic, Alexander, Rudloff, Udo, Thorgeirsson, Snorri S., Avital, Itzhak
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911882/
https://ncbi.nlm.nih.gov/pubmed/27326258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.10047
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki